Report cover image

Global Medications for Alcohol Use Disorder (AUD) Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 199 Pages
SKU # APRC20279006

Description

Summary

According to APO Research, the global Medications for Alcohol Use Disorder (AUD) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Medications for Alcohol Use Disorder (AUD) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Medications for Alcohol Use Disorder (AUD) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Medications for Alcohol Use Disorder (AUD) market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Medications for Alcohol Use Disorder (AUD) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Medications for Alcohol Use Disorder (AUD) market include Teva, Sun Pharmaceutical Industries, Merck KGaA, Mylan, Beijing Wellso Pharmaceutical Co, Zydus Pharmaceuticals, Taj Pharmaceuticals, TAGI Pharma Inc. and Rusan Pharma Ltd, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Medications for Alcohol Use Disorder (AUD), revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Medications for Alcohol Use Disorder (AUD), also provides the value of main regions and countries. Of the upcoming market potential for Medications for Alcohol Use Disorder (AUD), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Medications for Alcohol Use Disorder (AUD) revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Medications for Alcohol Use Disorder (AUD) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Medications for Alcohol Use Disorder (AUD) company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.

Medications for Alcohol Use Disorder (AUD) Segment by Company


Teva

Sun Pharmaceutical Industries

Merck KGaA

Mylan

Beijing Wellso Pharmaceutical Co

Zydus Pharmaceuticals

Taj Pharmaceuticals

TAGI Pharma Inc.

Rusan Pharma Ltd

Lundbeck

Glenmark Pharmaceuticals

Alvogen

Alkermes

Medications for Alcohol Use Disorder (AUD) Segment by Type


Acamprosate

Naltrexone

Disulfiram

Other

Medications for Alcohol Use Disorder (AUD) Segment by Application


Hospital

Rehabilitation Institutions

Others

Medications for Alcohol Use Disorder (AUD) Segment by Region


North America


United States

Canada

Mexico

Europe


Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific


China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America


Brazil

Argentina

Chile

Middle East & Africa


Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Medications for Alcohol Use Disorder (AUD) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Medications for Alcohol Use Disorder (AUD) key companies, revenue, market share, and recent developments.
3. To split the Medications for Alcohol Use Disorder (AUD) breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Medications for Alcohol Use Disorder (AUD) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Medications for Alcohol Use Disorder (AUD) significant trends, drivers, influence factors in global and regions.
6. To analyze Medications for Alcohol Use Disorder (AUD) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medications for Alcohol Use Disorder (AUD) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Medications for Alcohol Use Disorder (AUD) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medications for Alcohol Use Disorder (AUD).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Medications for Alcohol Use Disorder (AUD) industry.
Chapter 3: Detailed analysis of Medications for Alcohol Use Disorder (AUD) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Medications for Alcohol Use Disorder (AUD) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Medications for Alcohol Use Disorder (AUD) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

199 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Medications for Alcohol Use Disorder (AUD) Market Size, 2020 VS 2024 VS 2031
1.3 Global Medications for Alcohol Use Disorder (AUD) Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Medications for Alcohol Use Disorder (AUD) Market Dynamics
2.1 Medications for Alcohol Use Disorder (AUD) Industry Trends
2.2 Medications for Alcohol Use Disorder (AUD) Industry Drivers
2.3 Medications for Alcohol Use Disorder (AUD) Industry Opportunities and Challenges
2.4 Medications for Alcohol Use Disorder (AUD) Industry Restraints
3 Medications for Alcohol Use Disorder (AUD) Market by Company
3.1 Global Medications for Alcohol Use Disorder (AUD) Company Revenue Ranking in 2024
3.2 Global Medications for Alcohol Use Disorder (AUD) Revenue by Company (2020-2025)
3.3 Global Medications for Alcohol Use Disorder (AUD) Company Ranking (2023-2025)
3.4 Global Medications for Alcohol Use Disorder (AUD) Company Manufacturing Base and Headquarters
3.5 Global Medications for Alcohol Use Disorder (AUD) Company Product Type and Application
3.6 Global Medications for Alcohol Use Disorder (AUD) Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Medications for Alcohol Use Disorder (AUD) Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Medications for Alcohol Use Disorder (AUD) Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Medications for Alcohol Use Disorder (AUD) Market by Type
4.1 Medications for Alcohol Use Disorder (AUD) Type Introduction
4.1.1 Acamprosate
4.1.2 Naltrexone
4.1.3 Disulfiram
4.1.4 Other
4.2 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Type
4.2.1 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Type (2020-2031)
4.2.3 Global Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type (2020-2031)
5 Medications for Alcohol Use Disorder (AUD) Market by Application
5.1 Medications for Alcohol Use Disorder (AUD) Application Introduction
5.1.1 Hospital
5.1.2 Rehabilitation Institutions
5.1.3 Others
5.2 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Application
5.2.1 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Application (2020-2031)
5.2.3 Global Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application (2020-2031)
6 Medications for Alcohol Use Disorder (AUD) Regional Value Analysis
6.1 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Region (2020-2031)
6.2.1 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Region: 2020-2025
6.2.2 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Medications for Alcohol Use Disorder (AUD) Sales Value (2020-2031)
6.3.2 North America Medications for Alcohol Use Disorder (AUD) Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Medications for Alcohol Use Disorder (AUD) Sales Value (2020-2031)
6.4.2 Europe Medications for Alcohol Use Disorder (AUD) Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Medications for Alcohol Use Disorder (AUD) Sales Value (2020-2031)
6.5.2 Asia-Pacific Medications for Alcohol Use Disorder (AUD) Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Medications for Alcohol Use Disorder (AUD) Sales Value (2020-2031)
6.6.2 South America Medications for Alcohol Use Disorder (AUD) Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Medications for Alcohol Use Disorder (AUD) Sales Value (2020-2031)
6.7.2 Middle East & Africa Medications for Alcohol Use Disorder (AUD) Sales Value Share by Country, 2024 VS 2031
7 Medications for Alcohol Use Disorder (AUD) Country-level Value Analysis
7.1 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Country (2020-2031)
7.2.1 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Country (2020-2025)
7.2.2 Global Medications for Alcohol Use Disorder (AUD) Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.3.2 USA Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.4.2 Canada Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.6.2 Germany Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.7.2 France Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.7.3 France Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.9.2 Italy Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.10.2 Spain Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.11.2 Russia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.14.2 China Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.14.3 China Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.15.2 Japan Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.17.2 India Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.17.3 India Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.18.2 Australia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.22.2 Chile Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.24.2 Peru Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.26.2 Israel Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.27.2 UAE Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.29.2 Iran Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Medications for Alcohol Use Disorder (AUD) Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Medications for Alcohol Use Disorder (AUD) Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Medications for Alcohol Use Disorder (AUD) Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Teva
8.1.1 Teva Comapny Information
8.1.2 Teva Business Overview
8.1.3 Teva Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2020-2025)
8.1.4 Teva Medications for Alcohol Use Disorder (AUD) Product Portfolio
8.1.5 Teva Recent Developments
8.2 Sun Pharmaceutical Industries
8.2.1 Sun Pharmaceutical Industries Comapny Information
8.2.2 Sun Pharmaceutical Industries Business Overview
8.2.3 Sun Pharmaceutical Industries Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2020-2025)
8.2.4 Sun Pharmaceutical Industries Medications for Alcohol Use Disorder (AUD) Product Portfolio
8.2.5 Sun Pharmaceutical Industries Recent Developments
8.3 Merck KGaA
8.3.1 Merck KGaA Comapny Information
8.3.2 Merck KGaA Business Overview
8.3.3 Merck KGaA Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2020-2025)
8.3.4 Merck KGaA Medications for Alcohol Use Disorder (AUD) Product Portfolio
8.3.5 Merck KGaA Recent Developments
8.4 Mylan
8.4.1 Mylan Comapny Information
8.4.2 Mylan Business Overview
8.4.3 Mylan Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2020-2025)
8.4.4 Mylan Medications for Alcohol Use Disorder (AUD) Product Portfolio
8.4.5 Mylan Recent Developments
8.5 Beijing Wellso Pharmaceutical Co
8.5.1 Beijing Wellso Pharmaceutical Co Comapny Information
8.5.2 Beijing Wellso Pharmaceutical Co Business Overview
8.5.3 Beijing Wellso Pharmaceutical Co Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2020-2025)
8.5.4 Beijing Wellso Pharmaceutical Co Medications for Alcohol Use Disorder (AUD) Product Portfolio
8.5.5 Beijing Wellso Pharmaceutical Co Recent Developments
8.6 Zydus Pharmaceuticals
8.6.1 Zydus Pharmaceuticals Comapny Information
8.6.2 Zydus Pharmaceuticals Business Overview
8.6.3 Zydus Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2020-2025)
8.6.4 Zydus Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio
8.6.5 Zydus Pharmaceuticals Recent Developments
8.7 Taj Pharmaceuticals
8.7.1 Taj Pharmaceuticals Comapny Information
8.7.2 Taj Pharmaceuticals Business Overview
8.7.3 Taj Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2020-2025)
8.7.4 Taj Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio
8.7.5 Taj Pharmaceuticals Recent Developments
8.8 TAGI Pharma Inc.
8.8.1 TAGI Pharma Inc. Comapny Information
8.8.2 TAGI Pharma Inc. Business Overview
8.8.3 TAGI Pharma Inc. Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2020-2025)
8.8.4 TAGI Pharma Inc. Medications for Alcohol Use Disorder (AUD) Product Portfolio
8.8.5 TAGI Pharma Inc. Recent Developments
8.9 Rusan Pharma Ltd
8.9.1 Rusan Pharma Ltd Comapny Information
8.9.2 Rusan Pharma Ltd Business Overview
8.9.3 Rusan Pharma Ltd Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2020-2025)
8.9.4 Rusan Pharma Ltd Medications for Alcohol Use Disorder (AUD) Product Portfolio
8.9.5 Rusan Pharma Ltd Recent Developments
8.10 Lundbeck
8.10.1 Lundbeck Comapny Information
8.10.2 Lundbeck Business Overview
8.10.3 Lundbeck Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2020-2025)
8.10.4 Lundbeck Medications for Alcohol Use Disorder (AUD) Product Portfolio
8.10.5 Lundbeck Recent Developments
8.11 Glenmark Pharmaceuticals
8.11.1 Glenmark Pharmaceuticals Comapny Information
8.11.2 Glenmark Pharmaceuticals Business Overview
8.11.3 Glenmark Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2020-2025)
8.11.4 Glenmark Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio
8.11.5 Glenmark Pharmaceuticals Recent Developments
8.12 Alvogen
8.12.1 Alvogen Comapny Information
8.12.2 Alvogen Business Overview
8.12.3 Alvogen Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2020-2025)
8.12.4 Alvogen Medications for Alcohol Use Disorder (AUD) Product Portfolio
8.12.5 Alvogen Recent Developments
8.13 Alkermes
8.13.1 Alkermes Comapny Information
8.13.2 Alkermes Business Overview
8.13.3 Alkermes Medications for Alcohol Use Disorder (AUD) Revenue and Gross Margin (2020-2025)
8.13.4 Alkermes Medications for Alcohol Use Disorder (AUD) Product Portfolio
8.13.5 Alkermes Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.